Massar Capital Management LP Buys Shares of 3,426 ICU Medical, Inc. (NASDAQ:ICUI)

Massar Capital Management LP acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,426 shares of the medical instruments supplier's stock, valued at approximately $532,000.

Other institutional investors have also modified their holdings of the company. Harvest Fund Management Co. Ltd acquired a new stake in shares of ICU Medical in the fourth quarter valued at $33,000. Murphy & Mullick Capital Management Corp purchased a new stake in shares of ICU Medical during the fourth quarter valued at $52,000. Venturi Wealth Management LLC boosted its position in shares of ICU Medical by 64.0% in the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 206 shares during the period. Russell Investments Group Ltd. increased its stake in ICU Medical by 88.8% in the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 300 shares in the last quarter. Finally, Sterling Capital Management LLC increased its stake in ICU Medical by 813.5% in the 4th quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock worth $105,000 after purchasing an additional 602 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

ICU Medical Stock Down 1.1 %

ICUI traded down $1.50 on Friday, reaching $135.66. 164,550 shares of the company traded hands, compared to its average volume of 274,007. The stock's 50 day moving average price is $143.81 and its 200-day moving average price is $157.93. ICU Medical, Inc. has a 52-week low of $95.44 and a 52-week high of $196.26. The company has a market cap of $3.34 billion, a price-to-earnings ratio of -29.68 and a beta of 0.86. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

Analyst Ratings Changes

Several brokerages have issued reports on ICUI. Raymond James set a $97.00 target price on shares of ICU Medical in a research note on Wednesday, March 12th. StockNews.com lowered ICU Medical from a "buy" rating to a "hold" rating in a research report on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Finally, KeyCorp reduced their price target on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ICU Medical currently has an average rating of "Moderate Buy" and an average target price of $162.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.